57
Participants
Start Date
February 28, 2011
Primary Completion Date
August 31, 2012
Study Completion Date
February 28, 2015
Tesetaxel
Tesetaxel capsules will be administered orally once every 21 days until progression, as defined by Prostate Cancer Working Group 2 (PCWG2) criteria. The duration of protocol therapy will not exceed 12 months. Treatment will be initiated at a dose of 27 mg/m2; dose escalation to a maximum of 35 mg/m2 is allowed in Cycle 2 depending on tolerability.
RECRUITING
Memorial Sloan-Kettering Cancer Center, New York
RECRUITING
University of Wisconsin Carbone Cancer Center, Madison
RECRUITING
University of Michigan Health System, Ann Arbor
RECRUITING
The Cancer Institute of New Jersey, New Brunswick
Lead Sponsor
Genta Incorporated
INDUSTRY